Your browser doesn't support javascript.
loading
[Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients]. / Interferon convencional versus interferon peguilado associados à ribavirina no tratamento de pacientes coinfectados pelo vírus da hepatite C (genótipo 1) e da imunodeficiência humana.
Almeida, Paulo Roberto Lerias de; Tovo, Cristiane Valle; Rigo, Juliana Oliveira; Zanin, Pauline; Alves, Alexandro Vasquen; Mattos, Angelo Alves de.
Afiliação
  • Almeida PR; Serviços de Medicina Interna, Hospital Nossa Senhora da Conceição, Porto Alegre, RS. paulorlalmeida@terra.com.br
Arq Gastroenterol ; 46(2): 132-7, 2009.
Article em Pt | MEDLINE | ID: mdl-19578615
CONTEXT: It has been suggested that coinfected patients HCV/HIV must be treated with pegylated interferon associated to ribavirin (PEG+RBV), because of better taxes of sustained virological response when compared to those treated with conventional interferon associated to ribavirin (IFN+RBV). There are few studies in the literature comparing these two treatments options in this population. OBJECTIVE: To evaluate the sustained virological response to the treatment with IFN+RBV versus PEG+RBV in coinfected patients HCV/HIV genotype 1, in a public health program. METHODS: It is a cohort study, where the data of the coinfected patients treated with IFN+RBV (before 2002) or PEG+RBV (from 2002) during 48 weeks in the Brazilian Health Ministry program were reviewed. Demographic characteristics were evaluated (age, gender and weight), CD4 cell count and histopathology - inflammatory activity (A) and fibrosis grade, by METAVIR classification. The significance level adopted was 5%. RESULTS: Eighty one patients were evaluated, 22 treated with IFN+RBV and 59 treated with PEG+RBV. Both were similar relating to age, gender, weight, CD4 cell count and fibrosis grade. Those treated with IFN+RBV presented a greater proportion of A2+A3 patients than those treated with PEG+RBV (P<0.01). The sustained virological response was 14% versus 23% in those using IFN+RBV or PEG+RBV respectively (P = 0.54). The Odds Ratio was 1.9 (0.5 to 7.3). CONCLUSION: Coinfected patients HCV/HIV genotype 1 treated with PEG+RBV presented 1.9 more chance to obtain sustained virological response than those treated with IFN+RBV, however without statistical significance.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Infecções por HIV / Interferon-alfa / Hepatite C Crônica Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: Pt Revista: Arq Gastroenterol Ano de publicação: 2009 Tipo de documento: Article País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Infecções por HIV / Interferon-alfa / Hepatite C Crônica Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: Pt Revista: Arq Gastroenterol Ano de publicação: 2009 Tipo de documento: Article País de publicação: Brasil